Janex 1

HFFF2 recipient cells were treated with several inhibitors at the below concentrations simultaneously with sEV in medium supplemented with 10% (v/v) EV‐depleted FBS and 1% (v/v) A/A for 72 h. Treatment with inhibitors and sEV was repeated 72 h later and readout was determined after 72 h.
Small molecule inhibitor concentrations used for the screen: 40 µM PD98059 (targeting MEK1/2; ThermoFisher), 20 µM SB202190 (p38MAPK; Santa Cruz Biotech), 4µ M TGFB‐R1 (TGFBR1 kinase; Calbiochem), 8 µM VEGFR2 (VEGFR2; Calbiochem), 150 nM GSK429286A (ROCK1/2, Rho‐associated kinase; Abcam), 50 nM CPD22 (ILK, integrin‐linked kinase; Calbiochem), 1 µM CPG (MNK1/2; Calbiochem), 100 nM TORIN2 (mTOR, mammalian target of rapamycin; CAYMAN Chemical), 1µM RUXOLITINIB (JAK1/2 inhibitor; CAYMAN Chemical), 40 µM AG‐490 (JAK2/3 kinase; CAYMAN Chemical), 45 µM JANEX1 (JAK3 kinase; CAYMAN Chemical), 1 µM AG‐879 (protein Tyrosine Kinase; CAYMAN Chemical), 2 µM IMATINIB (tyrosine kinase; TK1; CAYMAN Chemical), 20 µM CAY10576 (IKKε, IκB kinase episilon; CAYMAN Chemical), 1.5 µM SUNITINIB (multi tyrosine kinase, multi‐TK; CAYMAN Chemical). Additional small molecular inhibitors used: 10 µM MLN120B (IKKβ, IκB kinase beta; MedChemExpress) and 10 µM BAY11‐7082 (IKKα/β, IκB kinase alpha/beta; Sigma‐Aldrich). Other pharmacological products: lymphotoxin‐β (Sigma Aldrich‐T7799) and Cisplatin (PHR1624; Sigma‐Aldrich).